Allison Cama

Allison Cama


Dr. Maria Zajac-Kaye


UF Health Cancer Center


Microbiology and Cell Science


Education Studies


Phi Mu Diversity, Equity and Inclusion member and Chairwoman (2020-2022), Alpha Epsilon Delta National Pre-Health Honor Society (2022-) , Homecoming and Gator Growl staff (2020-2022)

Academic Awards

Bright Futures Award Recipient (2020-2022), Nominee for The National Society of Leadership and Success (2021), Nominee for The National Society of Collegiate Scholars (2021)


Pre-Health volunteering in veterinary, medical and pre professional settings through Alpha Epsilon Delta

Research Interests

Cancer Therapeutics

Hobbies and Interests

Research and volunteering

Research Project

Effect of Thymidylate synthase inhibitors in pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal, RAS-driven cancer with the incidence increasing 60% over the last decade. Current chemotherapy does not produce an extension in survival and results in drug resistance. Thymidylate synthase (TYMS), an enzyme involved in DNA synthesis and repair, plays a direct role in promoting tumorigenesis. High levels of TYMS have been associated with poor clinical outcomes in many cancers. Zajac-Kaye Laboratory has shown that overexpression of TYMS cooperates with mutant KRAS to accelerate tumor progression of PDAC. The main goal of this project will be to study the effect of a new therapeutic approach in a PDAC xenograft model. We will determine the antitumoral effect of a TYMS inhibitor recently identified in the Zajac-Kaye Laboratory alone and combined separately with Temsirolimus or TAK-228, which are both KRAS/P13K/mTOR pathway inhibitors.